AlanJGreenMD

PubMed

• 241 citations
  MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
  Yuni K. Dewaraja, Michael Ljungberg, A J Green, Pat Zanzonico, Eric C. Frey, Wesley E. Bolch, A. Bertrand Brill, Mark Dunphy, Darrell R. Fisher, Roger W. Howell, Ruby ...> ;Journal of Nuclear Medicine. 2013 Dec 1
• Renal dosimetry.
  Wessels, B.W., Dale, R.G., Cremonesi, M., Meredith, R.F., Green, A.J., Brill, B., Bolch, W.E., Sgouros, G., Thomas, S.R.> ;Cancer Biother Radiopharm. 2010 Oct
• 29 citations
  A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
  Gairin Dancey, John Violet, Alessandra Malaroda, Alan J. Green, Surinder K. Sharma, Roslyn J. Francis, Shokri Othman, Sweta Parker, John R. Buscombe, Natalie Griffin, ...> ;Clinical Cancer Research. 2009 Dec 15
• 14 citations
  Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibo...
  Jason L. J. Dearling, AA Flynn, Uzma Qureshi, Stephen Whiting, Geoffrey M. Boxer, A J Green, Richard H. J. Begent, R. Barbara Pedley> ;Nuclear Medicine and Biology. 2009 Nov 1
• 52 citations
  A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
  Tim Meyer, Andrew M. Gaya, Gairin Dancey, Michael R.L. Stratford, Shokri Othman, Surinder K. Sharma, David Wellsted, N. Jane Taylor, J. James Stirling, Linda Poupard, ...> ;Clinical Cancer Research. 2009 Jul 1
• 127 citations
  MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy
  Barry W. Wessels, Mark Konijnenberg, Roger G. Dale, Hazel B. Breitz, Marta Cremonesi, Ruby F. Meredith, A J Green, Lionel G. Bouchet, A. Bertrand Brill, Wesley E. Bolc...> ;Journal of Nuclear Medicine. 2008 Nov 1
• 6 citations
  Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.
  J A Violet, Jason L. J. Dearling, A J Green, Richard H. J. Begent, RB Pedley> ;British Journal of Cancer. 2008 Aug 12
• 50 citations
  A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein ...
  A Mayer, Roslyn J. Francis, Surinder K. Sharma, Berend Tolner, Caroline J. Springer, Jan Martin, Geoff Boxer, Jimmy D. Bell, Alan J. Green, John A. Hartley, Clare Crui...> ;Clinical Cancer Research. 2006 Nov 1
• 8 citations
  Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.
  A J Green, Aiden A. Flynn, R. Barbara Pedley, Jason L. J. Dearling, Richard H. J. Begent> ;Cancer Biotherapy & Radiopharmaceuticals. 2004 Aug 25
• 43 citations
  Engineering antibodies for clinical applications in cancer.
  Kerry A. Chester, Barbara Pedley, Berend Tolner, John Violet, A Mayer, Surinder K. Sharma, Geoff Boxer, Alan J. Green, Sylvia Nagl, Richard H. J. Begent> ;Tumour Biology. 2004 Jan 1
• 45 citations
  Analysis of the Regional Uptake of Radiolabeled Deoxyglucose Analogs in Human Tumor Xenografts
  Jason L. J. Dearling, AA Flynn, Julie Sutcliffe-Goulden, Ingrid A. Petrie, Robert Boden, A J Green, Geoffrey M. Boxer, Richard H. J. Begent, R. Barbara Pedley> ;Journal of Nuclear Medicine. 2004 Jan 1
• 27 citations
  The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
  Aiden A. Flynn, R. Barbara Pedley, A J Green, Jason L. J. Dearling, Ethaar El-Emir, Geoffrey M. Boxer, Robert Boden, Richard H. J. Begent> ;Radiation Research. 2003 Feb 1
• 35 citations
  Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
  Joanne L. Casey, M. P. Napier, David J. King, RB Pedley, L. C. Chaplin, N Weir, L Skelton, A J Green, L D Hope-Stone, G. T. Yarranton, Richard H. J. Begent> ;British Journal of Cancer. 2002 May 6
• 8 citations
  A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection
  AA Flynn, A J Green, R. Barbara Pedley, Geoffrey M. Boxer, Jason L. J. Dearling, R Watson, Robert Boden, Richard H. J. Begent> ;Cancer. 2002 Feb 15
• 8 citations
  Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
  AA Flynn, R. Barbara Pedley, Alan J. Green, Geoffrey M. Boxer, Robert Boden, Richard H. J. Begent> ;Cancer Biotherapy & Radiopharmaceuticals. 2001 Oct 1
• 89 citations
  Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
  M. P. Napier, Surinder K. Sharma, Caroline J. Springer, Kd Bagshawe, A J Green, Janet Martin, Stephen M. Stribbling, N. Cushen, D O'Malley, R. H. J. Begent> ;Clinical Cancer Research. 2000 Mar 1
• 24 citations
  A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model
  Aiden A Flynn, Alan J. Green, Geoffrey M Boxer, Joanne L. Casey, R. Barbara Pedley, Richard H. J. Begent> ;International Journal of Radiation Oncology, Biology, Physics. 1999 Jan 1
• Join now to see all